Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by COR2ED. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by COR2ED or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Advanced HCC and not eligible for IO – what are the treatment options?

24:54
 
Share
 

Manage episode 442027515 series 3293376
Content provided by COR2ED. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by COR2ED or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

COR2ED Medical Education: Prof. Dr James Harding, Medical Oncologist at Memorial Sloan Kettering Cancer Center and Prof. Dr Sammy Saab, Gastroenterologist and Transplant Hepatologist at the David Geffen School of Medicine, both from the USA, discuss the treatment options for advanced hepatocellular carcinoma (HCC) patients who are not eligible for immunotherapy (IO) first line.

In this podcast, the experts give an overview of the current systemic treatment options for patients by looking into the results from different clinical trials and current guidelines, as the field is rapidly evolving since 2017. They discuss the patient cohorts who are not eligible for IO in first line, such as patients with underlying auto-immunity, impaired organ function and patients who decline IO.

The experts discuss the efficacy and safety data from the SHARP and Asia Pacific trials of sorafenib and from the REFLECT trial of lenvatinib, which are both tyrosine kinase inhibitors (TKIs) and available for the aforementioned patient cohorts. They also present their approach to toxicity management for patients receiving those TKIs.

  continue reading

90 episodes

Artwork
iconShare
 
Manage episode 442027515 series 3293376
Content provided by COR2ED. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by COR2ED or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

COR2ED Medical Education: Prof. Dr James Harding, Medical Oncologist at Memorial Sloan Kettering Cancer Center and Prof. Dr Sammy Saab, Gastroenterologist and Transplant Hepatologist at the David Geffen School of Medicine, both from the USA, discuss the treatment options for advanced hepatocellular carcinoma (HCC) patients who are not eligible for immunotherapy (IO) first line.

In this podcast, the experts give an overview of the current systemic treatment options for patients by looking into the results from different clinical trials and current guidelines, as the field is rapidly evolving since 2017. They discuss the patient cohorts who are not eligible for IO in first line, such as patients with underlying auto-immunity, impaired organ function and patients who decline IO.

The experts discuss the efficacy and safety data from the SHARP and Asia Pacific trials of sorafenib and from the REFLECT trial of lenvatinib, which are both tyrosine kinase inhibitors (TKIs) and available for the aforementioned patient cohorts. They also present their approach to toxicity management for patients receiving those TKIs.

  continue reading

90 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Copyright 2025 | Privacy Policy | Terms of Service | | Copyright
Listen to this show while you explore
Play